Safety study of SPD489 (lisdexamfetamine dimesylate) in schizophrenia
This study is completed in the United States. It is testing SPD489 (lisdexamfetamine dimesylate) for schizophrenia.
SchizophreniaDrugFrom 18 Years to 55 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether SPD489 (lisdexamfetamine dimesylate) may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive SPD489 (lisdexamfetamine dimesylate), attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: September 14, 2009
Recruitment status
Completed
Enrollment listed in the registry
92
Sponsor
Shire
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT00922272
Official title
A Phase 2, Multicenter Study With Open-label & Randomized Double-blind Placebo-controlled Withdrawal Phases to Evaluate the Efficacy, Safety, & Tolerability of SPD489 in Adults With Schizophrenia & Predominant Negative Symptoms Who Are Clinically Stable & Taking Stable Doses of Atypical Antipsychotic Medication
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00922272. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 27 sites
K&S Professional Research Services
Little Rock, Arkansas
Site status: Not listed — confirm with the team
South Coast Clinical Trials
Anaheim, California
Site status: Not listed — confirm with the team
Omega Clinical Trials
Anaheim, California
Site status: Not listed — confirm with the team
Clinical Innovations
Costa Mesa, California
Site status: Not listed — confirm with the team
Collaborative Neuroscience Network, Inc.
Garden Grove, California
Site status: Not listed — confirm with the team
Apostle Clinical Trials, Inc.
Long Beach, California
Site status: Not listed — confirm with the team
Excell Research, Inc.
Oceanside, California
Site status: Not listed — confirm with the team
Southcoast Clinical Trials
San Bernardino, California
Site status: Not listed — confirm with the team
CNRI San Diego & Los Angeles
San Diego, California
Site status: Not listed — confirm with the team
Affiliated Research Institute
San Diego, California
Site status: Not listed — confirm with the team
Artemis Institute for Clinical Research
San Diego, California
Site status: Not listed — confirm with the team
Neuropsychiatric Research Center of Orange County
Santa Ana, California
Site status: Not listed — confirm with the team
Accurate Clinical Trials
Kissimmee, Florida
Site status: Not listed — confirm with the team
Behavioral Clinical Research, INC
Lauderhill, Florida
Site status: Not listed — confirm with the team
Segal Institute for Clinical Research (Miami)
North Miami, Florida
Site status: Not listed — confirm with the team
Medical Research Group of Central Florida
Orange City, Florida
Site status: Not listed — confirm with the team
Stedman Clinical Trials
Tampa, Florida
Site status: Not listed — confirm with the team
Comprehensive NeuroScience
Atlanta, Georgia
Site status: Not listed — confirm with the team
Uptown Research Institute
Chicago, Illinois
Site status: Not listed — confirm with the team
J. Gary Booker, MD, APMC
Shreveport, Louisiana
Site status: Not listed — confirm with the team
CRI Worldwide, LLC.
Willingboro, New Jersey
Site status: Not listed — confirm with the team
Advanced Bio-Behavioral Sciences
Elmsford, New York
Site status: Not listed — confirm with the team
Comprehensive Neuroscience, Inc.
Hollis, New York
Site status: Not listed — confirm with the team
University of Cincinnati
Cincinnati, Ohio
Site status: Not listed — confirm with the team
CRI Worldwide
Philadelphia, Pennsylvania
Site status: Not listed — confirm with the team
Community Clinical Research, Inc.
Austin, Texas
Site status: Not listed — confirm with the team
University Hills Clinical Research
Irving, Texas
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate). Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Shire, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
